Temasek’s venture capital arm Vertex Ventures has participated in a $47.6 million Series A financing round in Palleon Pharmaceuticals, a US-based biotechnology firm that focuses on developing glycoimmune checkpoint inhibitors to treat cancer.
Continue reading this story with a subscription to DealStreetAsia.
Unlock your competitive advantage in a rapidly evolving scape. Our packages come with exclusive access to archives, content, data, discount on summit tickets & more. Be a part of our growing community now.